Orphan Disease Natural History Grants Latest FDA Incentive For Drug Development
Agency will make $2m available in 2017.
You may also be interested in...
‘Elites’ Need To Understand Clinical Development Remains Necessary For Drug Discovery, Woodcock Says
US FDA’s principal deputy commissioner continues to preach clinical trial reform, saying stakeholders must remember that understanding a molecule does not equate to understanding its impact on the body.
NIH plans to select two dozen groups to participate in a Global Rare Disease Patient Registry pilot project, which FDA hopes will lead to a better understanding of the conditions and speed drug development.
CDER Director Janet Woodcock says rare disease advocates should consider organizing patients to study a rare disease history and progression.